Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial

Ingrid Demmelmaier, Hannah L Brooke, Anna Henriksson, Anne-Sophie Mazzoni, Ann Christin Helgesen Bjørke, Helena Igelström, Anna-Karin Ax, Katarina Sjövall, Maria Hellbom, Ronnie Pingel, Henrik Lindman, Silvia Johansson, Galina Velikova, Truls Raastad, Laurien M Buffart, Pernilla Åsenlöf, Neil K Aaronson, Bengt Glimelius, Peter Nygren, Birgitta JohanssonSussanne Börjeson, Sveinung Berntsen, Karin Nordin

Forskningsoutput: TidskriftsbidragArtikelPeer review

26 Citeringar (Scopus)


Exercise during cancer treatment improves cancer-related fatigue (CRF), but the importance of exercise intensity for CRF is unclear. We compared the effects of high- vs low-to-moderate-intensity exercise with or without additional behavior change support (BCS) on CRF in patients undergoing (neo-)adjuvant cancer treatment. This was a multicenter, 2x2 factorial design randomized controlled trial (Clinical Trials NCT02473003) in Sweden. Participants recently diagnosed with breast (n = 457), prostate (n = 97) or colorectal (n = 23) cancer undergoing (neo-)adjuvant treatment were randomized to high intensity (n = 144), low-to-moderate intensity (n = 144), high intensity with BCS (n = 144) or low-to-moderate intensity with BCS (n = 145). The 6-month exercise intervention included supervised resistance training and home-based endurance training. CRF was assessed by Multidimensional Fatigue Inventory (MFI, five subscales score range 4-20), and Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-F, score range 0-52). Multiple linear regression for main factorial effects was performed according to intention-to-treat, with post-intervention CRF as primary endpoint. Overall, 577 participants (mean age 58.7 years) were randomized. Participants randomized to high- vs low-to-moderate-intensity exercise had lower physical fatigue (MFI Physical Fatigue subscale; mean difference -1.05 [95% CI: -1.85, -0.25]), but the difference was not clinically important (ie <2). We found no differences in other CRF dimensions and no effect of additional BCS. There were few minor adverse events. For CRF, patients undergoing (neo-)adjuvant treatment for breast, prostate or colorectal cancer can safely exercise at high- or low-to-moderate intensity, according to their own preferences. Additional BCS does not provide extra benefit for CRF in supervised, well-controlled exercise interventions.

Sidor (från-till)1144-1159
Antal sidor15
TidskriftScandinavian Journal of Medicine and Science in Sports
StatusPublicerad - 2021
Externt publiceradJa

Nationell ämneskategori

  • Cancer och onkologi (30203)


Fördjupa i forskningsämnen för ”Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här